Mendus’s Q126 results reflect the execution of its expanded clinical strategy for vididencel, with the key highlight being the launch of the Phase I VITAL-CML trial in chronic myeloid leukaemia (CML), marking the start of clinical development in this indication.
The programme targets patients with suboptimal responses to tyrosine kinase inhibitors (TKIs), with initial safety and early molecular efficacy data expected in H226. In acute myeloid leukaemia (AML), Mendus confirmed that the CADENCE Phase IIb trial (combination with oral azacitidine in chemo-fit AML patients) remains on track to enrol the first 20 patients in H126.
The company also announced a collaboration with the Olivia Newton John Cancer Research Institute to support the Phase Ib DIVA study (combination with venetoclax and azacitidine, Ven-Aza, in chemo-unfit AML patients); we expect this to commence from mid-2026.
Financially, the Q126 operating loss narrowed by 33% y-o-y to SEK20.1m, while the quarter-end gross cash position was SEK74.1m, reflecting the SEK30m drawn from its existing SEK50m loan facility with Fenja Capital during January 2026.